Opthea’s staff are paying for its clinical failures. Days after back-to-back flops sank an eye disease asset, the biotech ...

Troubled biotech stock Opthea (ASX:OPT), still in the process of crisis talks with investors, has flagged a workforce ...

Opthea’s eye disease drug has failed its second phase 3 trial in a week, leaving the Australian biotech to discard the entire wet age-related macular degeneration (AMD) program.

The announcement follows the decision to discontinue the COAST and ShORe trials in wet age-related macular degeneration after the COAST trial failed to meet its primary endpoint.

ShORe Phase 3 topline results accelerated; trial did not meet primary endpoint of mean change in BCVA from baseline to week 52Opthea and DFA ...

Phil King discusses the Opthea fiasco, his current outlook and whether we’ve seen the bottom in equity markets.

Opthea said it agreed with the investors in its development funding agreement to end development of sozinibercept in wet AMD, and that the move wouldn't constitute a termination event under the ...

(RTTNews) - Opthea Limited (OPT), a clinical-stage biopharmaceutical company focused on retinal diseases, including wet age-related macular degeneration or wet AMD, announced Monday that its ...

The hedge fund run by veteran stockpicker Phil King has told investors that the eye treatment play is worth 20¢ per share. It is the company’s largest investor.

Sozinibercept combination therapy was well tolerated. Following the receipt of these results, Opthea has undertaken a thorough review of the data to ensure both its accuracy and integrity.

Following the negative results of the COAST Phase 3 trial announced on 24 March 2025, Opthea determined that the most appropriate course of action for wet AMD patients, shareholders, and other ...